CAI vs RNLXY: stock comparison and AI forecast
Caris Life Sciences, Inc. (CAI) and Renalytix Plc (RNLXY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CAI Caris Life Sciences, Inc.
- Price
- $34.33 +80.7% · 6M
- Market Cap
- $9.70B
- P/E Ratio
- 7.2x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
RNLXY Renalytix Plc
- Market Cap
- n/a
- P/E Ratio
- –
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- Both companies share the SEC industry classification Services-Medical Laboratories.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CAI | RNLXY |
|---|---|---|
| Market Cap | $9.70B | – |
| P/E Ratio | 7.23x | – |
| P/B Ratio | 16.40x | – |
| EPS | $4.75 | $-0.12 |
| Book Value/Share | $2.09 | – |
| Revenue/Share | $3.93 | – |
| FCF/Share | $0.44 | – |
Profitability & Margins
| Metric | CAI | RNLXY |
|---|---|---|
| ROA | – | -520.3% |
| ROIC | 9.2% | – |
| Gross Margin | – | 10.4% |
| Operating Margin | 8.6% | -1332.8% |
| Net Margin | – | -1179.8% |
| EBT Margin | 0.2% | -1471.3% |
| Tax Rate | -4.5% | -0.0% |
Financial Health
| Metric | CAI | RNLXY |
|---|---|---|
| Current Ratio | 5.53x | – |
| D/E Ratio | 1.08x | – |
| Financial Leverage | 2.08x | – |
| Interest Coverage | 2.9x | -26.3x |
| Working Capital | $866M | – |
Cash Flow
| Metric | CAI | RNLXY |
|---|---|---|
| Operating Cash Flow | $169M | -$26M |
| Free Cash Flow | $124M | – |
| Capital Spending | -$45M | – |
| FCF/Sales | 11.2% | – |
| CapEx/Sales | 4.0% | – |
Operational Efficiency
| Metric | CAI | RNLXY |
|---|---|---|
| Asset Turnover | 0.90x | – |
| Receivables Turnover | 9.5x | – |
| Fixed Assets Turnover | 11.6x | – |
| Days Sales Outstanding | 38 days | – |
Income Statement
| Metric | CAI | RNLXY |
|---|---|---|
| Total Revenue | $1.11B | – |
| Operating Income | $95M | -$28M |
| Net Income | – | -$25M |
| R&D Expense | $140M | $9M |
| SG&A Expense | $672M | – |
| Cost of Goods Sold | – | $2M |
Dividend & Shareholder Information
| Metric | CAI | RNLXY |
|---|---|---|
| Shares Outstanding | 283M | – |
CAI vs RNLXY: stock comparison and AI forecast
Which one does Intratio's AI model rank higher, CAI or RNLXY?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.